Cardiff Lexington Announces 3rd Quarter 2022 Financial Results

Rhea-AI Summary

Cardiff Lexington Corporation (OTC PINK:CDIX) reported its 3rd quarter financial results for the period ending September 30, 2022. Key highlights include:

• Stockholders' Equity: Increased by 131%, totaling $6.4 million.
• Total Assets: Rose by 43%, reaching $15.9 million.
• Revenue: Grew by 47%, amounting to $9.4 million.
• Gross Margin: Up by 43%, totaling $6 million.
• Net Loss: Decreased by $1.9 million to ($813,054).

Management expressed optimism about moving beyond cash flow survival.

Positive

• 131% increase in Stockholders' Equity, reaching $6.4 million.
• 43% growth in Total Assets to $15.9 million.
• 47% rise in Revenue to $9.4 million.
• 43% increase in Gross Margin, totaling $6 million.
• Net Loss decreased by $1.9 million, improving financial outlook.

Negative

• Ongoing challenges due to prior delinquent reporting status and cash flow constraints.

FT. LAUDERDALE, FL / ACCESSWIRE / January 9, 2023 / Cardiff Lexington Corporation (OTC PINK:CDIX) announced today financial results for its 3^rd quarter ended September 30, 2022.

Total Stockholder' Equity
For the Twelve Months Ended December 31, 2020	$2,781,364
For the Nine Months Ended September 30, 2022	$6,417,788
131% Net Increase is Stockholders Equity	$3,636,424
Total Assets End of Period
For the Twelve Months Ended December 31, 2021	$11,159,951
For the Nine Months Ended September 30, 2022	$15,958,345
43% Net Increase in Total Assets	$4,798,394
Revenue
For the Nine Months Ended September 30, 2021	$6,424,587
For the Nine Months Ended September 30, 2022	$9,432,481
47% Net Increase in Nine Month Revenue	$3,007,894
Gross Margin
For the Nine Months Ended September 30, 2021	$4,222,040
For the Nine Months Ended September 30, 2022	$6,026,267
43% Net Increase in Semi-Annual Gross Margin	$1,804,227
Profit/Loss from Operations
For the Nine Months Ended September 30, 2021	($1,665,830)
For the Nine Months Ended September 30, 2022	$3,325,317
Net Increase in Profit/Loss from Operations	$4,991,147
Net Profit/Loss for the Nine Month Period
For the Nine Months Ended September 30, 2021	($2,810,930)
For the Nine Months Ended September 30, 2022	($813,054)
Net Decrease in Loss for the Period	$1,997,876

For the three quarters ending in September, the Company reported increased Stockholders' Equity of 131%, a $3.6 million dollar increase; increased Total Assets of 43%, a $4.8 million dollar increase; increased Revenue of 47%, a $3.0 million dollar increase; increased Gross Margin of 43%, a 1.8 million dollar increase; increased Profit from Operations for the nine month period by $4.99 million dollars; and decreased the Net Loss for the nine month period by $1.99 million dollars.

Over the past eighteen months operating under difficult conditions and severe cash flow constraints derived from the Company's delinquent reporting status originating from a dispute between auditors, management has consistently improved revenue, margins, and the balance sheet. The Company has divested of smaller underperforming assets which were not aligned with our strategy moving forward and positioned the Company for synergistic future acquisitions within the healthcare segment.

Alex Cunningham Cardiff Lexington CEO stated, ""We are very relieved, as well as excited, to report this 3^rd quarter 2022 financial disclosure. The Company finally has regained its status as a, current, fully reporting, public company. It has been a difficult and trying process." Cunningham further stated, "This accomplishment empowers management to finally turn the page and its focus beyond cash flow survival and sustained internal revenue growth while maximizing margins, to now, additionally, move toward acquiring new capitalization required to maximize profitability and fund exponential growth through new strategically aligned acquisitions. This is also a major step forward towards proprietary broker-dealers being able to publish competing quotations and provide continuous market making of the Company's shares on the OTC Pink Market. With over $6 million dollars in Stockholders' Equity, consecutive years exceeding $10 million in annual Revenue, and with approximately a $5 million increase in profit from operations, the Company management looks forward announcing future developments and to reporting 2022 year end, and 2023, 1^st quarter performance."

About Cardiff Lexington Corporation: Cardiff Lexington Corporation provides healthcare and financial services in the United States. The Company provides a full range of diagnostic and surgical services for injuries and disorders throughout the State of Florida with nine current locations. The company provides national tax resolution bookkeeping, and tax preparation service to individuals and companies that have federal and state tax liabilities. It also engages in the real estate currently developing 27 medium and high-density acres of dedicated riverfront property on the Salmon River, in Salmon Idaho adjacent to the Frank Church Wilderness Park, the largest wilderness park in the lower 48 states. The Company's "Buy and Build" acquisition and value creation strategy targets acquisition of middle market private niche companies synergistically leveraging data and resources across similar target markets as wholly owned subsidiaries. Fundamental to the Cardiff Lexington strategy is the service-based partnership culture which emphasizes core values, teamwork, accountability, and performance. The Cardiff Lexington umbrella provides its subsidiary companies a proven, experienced management team led by strong and talented executives and advisors providing, added management value operationally. The Company's focus is not geographic-specific, but rather proven management, market, and margin - the Company is opportunity oriented. Cardiff Lexington Corporation was incorporated in 2001 and is headquartered in Fort Lauderdale, Florida.

FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.

Contact:

Investor Relations
800-628-2100 ext. 705
investorsrelations@cardifflexington.com

SOURCE: Cardiff Lexington Corporation

View source version on accesswire.com:
https://www.accesswire.com/734355/Cardiff-Lexington-Announces-3rd-Quarter-2022-Financial-Results

FAQ

What were Cardiff Lexington's financial results for the 3rd quarter of 2022?

Cardiff Lexington reported a 131% increase in Stockholders' Equity, reaching $6.4 million, and a 47% rise in Revenue to $9.4 million.

How did Cardiff Lexington improve its financial position in 2022?

The company saw total assets increase by 43% to $15.9 million and reduced its net loss by $1.9 million.

What is the stock performance outlook for Cardiff Lexington (CDIX) following the recent press release?

Management expressed optimism about future growth and capital acquisition strategies.

How does Cardiff Lexington plan to address its past cash flow constraints?

The company aims to focus on revenue growth and strategic acquisitions in the healthcare segment.